Prediction of site-specific metastases in surgically treated nonmetastatic renal cell cancer. Changes of follow-up protocol.
Frank
I
I
Mayo Medicial School, Mayo Clinic, Rochester, MN 55905, USA.
Zincke
H
H
D000008:Abdominal Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery; D000465:Algorithms; D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D018450:Disease Progression; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis